Latigo Biotherapeutics filed for an IPO to fund clinical development of a non-opioid pain pipeline built around Nav1.8 inhibition, positioning its oral candidate LTG-001 for Phase 3 studies in bunion surgery and other post-surgical settings. The company is betting on differentiation from Vertex’s Journax (suzetrigine), while also advancing LTG-321 in Phase 2 for osteoarthritis.